Biogen (BSP:BIIB34) Equity-to-Asset

: 0.55 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biogen's Total Stockholders Equity for the quarter that ended in Dec. 2022 was R$70,277 Mil. Biogen's Total Assets for the quarter that ended in Dec. 2022 was R$128,796 Mil. Therefore, Biogen's Equity to Asset Ratio for the quarter that ended in Dec. 2022 was 0.55.

The historical rank and industry rank for Biogen's Equity-to-Asset or its related term are showing as below:

BSP:BIIB34' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44 Med: 0.76 Max: 0.96
Current: 0.55

During the past 13 years, the highest Equity to Asset Ratio of Biogen was 0.96. The lowest was 0.44. And the median was 0.76.

BSP:BIIB34's Equity-to-Asset is ranked worse than
53.71% of 1119 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs BSP:BIIB34: 0.55

Biogen Equity-to-Asset Historical Data

The historical data trend for Biogen's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

0.52

0.49

0.44

0.46

0.55

Biogen Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Equity-to-Asset																0.46	0.48	0.47	0.51	0.55

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biogen's Equity-to-Asset falls in comparison to its industry or sector. The grey bar indicates the Equity-to-Asset's extreme value range as defined by GuruFocus.

Biogen Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biogen's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	70277.344644847	/	128796.07611223
	=	0.55

Biogen's Equity to Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

Equity to Asset (Q: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	70277.344644847	/	128796.07611223
	=	0.55

Biogen (BSP:BIIB34) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Biogen Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biogen's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines